Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2024-06-03 Regulatory Filings
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청) (5가 수막구균 접합백신 EuNmCV-5 유엔엠씨브이-파이브 멀티주의 제2/3상 아프리카 임상시험계획승인 신청IND)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically the application for approval of a Phase 2/3 clinical trial for a 5-valent meningococcal conjugate vaccine. Since this is a formal regulatory disclosure of a material event (clinical trial application) that does not fit into specific categories like earnings, dividends, or board changes, it is classified as a general regulatory filing.
2024-06-03 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report changes in share ownership by major shareholders or insiders, which corresponds to the 'Major Shareholding Notification' (MRQ) category in the provided schema.
2024-05-31 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'EuBiologics' (주식회사 유바이오로직스) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-13 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (대상포진 예방 백신 EuHZV(유에이치지브이)주의 제1상 국내 임상시험계획 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Eubiologics regarding the approval of a Phase 1 clinical trial for a shingles vaccine. It is a formal disclosure of a material business event (clinical trial approval) submitted to the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or director dealings, and is a standard regulatory disclosure of a corporate event, it falls under the 'Regulatory Filings' category.
2024-04-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details changes in share ownership by a major shareholder (Bionote, Inc.) in the issuing company (U-BioLogics). This type of filing is a standard regulatory disclosure for insider or major shareholder transactions, which falls under the 'Director's Dealing' category in the provided schema.
2024-04-12 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically '장내매수' or open market purchases) by a major shareholder (Bionote, Inc.) in the issuer (U-BioLogics). This document type is specifically used to notify the market when a shareholder crosses significant ownership thresholds, which corresponds to the 'Major Shareholding Notification' category.
2024-04-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.